Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial
BackgroundThe efficacy and mechanism of Fufang Danshen dripping pills (FFDS) in the secondary prevention of stable coronary heart disease (SCHD) is currently undetermined. This study aims to investigate the efficacy and preliminary mechanism by which FFDS may impact the progression of SCHD.MethodsBa...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1506917/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582896587636736 |
|---|---|
| author | Li-qin Meng Li-qin Meng Pei-ying Huang Qing-min Li Yu-chao Feng Yu-chao Feng Yu-chao Feng Ding-jian Li Guang-long Wu Bo-wen Ao Guo-chao Wu Guo-xiong Zhang Bo-jun Chen Bo-jun Chen Bo-jun Chen |
| author_facet | Li-qin Meng Li-qin Meng Pei-ying Huang Qing-min Li Yu-chao Feng Yu-chao Feng Yu-chao Feng Ding-jian Li Guang-long Wu Bo-wen Ao Guo-chao Wu Guo-xiong Zhang Bo-jun Chen Bo-jun Chen Bo-jun Chen |
| author_sort | Li-qin Meng |
| collection | DOAJ |
| description | BackgroundThe efficacy and mechanism of Fufang Danshen dripping pills (FFDS) in the secondary prevention of stable coronary heart disease (SCHD) is currently undetermined. This study aims to investigate the efficacy and preliminary mechanism by which FFDS may impact the progression of SCHD.MethodsBased on randomization, we administered oral FFDS to 30 patients with SCHD in addition to conventional treatment for 30 days. After treatment, three-months major adverse cardiovascular events (MACE) were assessed as the primary outcome. Additionally, we evaluated the patients' Seattle Angina Questionnaire score, blood pressure, circulating levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, C-reactive protein, platelets, alanine aminotransferase, aspartate aminotransferase, serum creatinine, and fasting blood glucose as the secondary outcomes. Furthermore, we utilized mass spectrometry analysis, network pharmacology, and lipidomics to predict the potential mechanisms of FFDS in the treatment of SCHD.ResultsFollowing treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P = 0.013) and a reduction in the frequency of angina episodes (P = 0.021). We conducted mass spectrometry analysis on FFDS and identified 236 chemical components. Lipidomics further confirmed triglycerides as key lipids affected by FFDS. By integrating these findings with network pharmacology targets, we highlighted the potential roles of LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT in fat digestion, absorption, and metabolism pathways, suggesting their involvement in FFDS's treatment of SCHD by reducing triglycerides.ConclusionIn individuals with SCHD, the administration of FFDS has been shown to effectively reduce circulating triglyceride levels and decrease the frequency of angina episodes. This therapeutic effect is likely due to the active components of FFDS targeting key proteins: LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT.Clinical Trial Registrationhttps://www.chictr.org.cn/, identifier (ChiCTR2400080149). |
| format | Article |
| id | doaj-art-218f296a884043c8ba719bff530bd2db |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-218f296a884043c8ba719bff530bd2db2025-01-29T06:45:47ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-01-011210.3389/fcvm.2025.15069171506917Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trialLi-qin Meng0Li-qin Meng1Pei-ying Huang2Qing-min Li3Yu-chao Feng4Yu-chao Feng5Yu-chao Feng6Ding-jian Li7Guang-long Wu8Bo-wen Ao9Guo-chao Wu10Guo-xiong Zhang11Bo-jun Chen12Bo-jun Chen13Bo-jun Chen14The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Geriatrics, Yangjiang People's Hospital, Yangjiang, ChinaEmergency Department, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, ChinaDepartment of Chinese Medicine, First People's Hospital of Chenzhou City, Chenzhou, ChinaThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, ChinaEmergency Department, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaDepartment of Laboratory, Yangjiang People's Hospital, Yangjiang, ChinaDepartment of Cardiology, Yangjiang People's Hospital, Yangjiang, ChinaDepartment of Cardiology, Yangjiang People's Hospital, Yangjiang, ChinaThe First Clinical Medical College, Guangdong Medical University, Zhanjiang, ChinaPhysical Examination Department, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, ChinaThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, ChinaEmergency Department, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaBackgroundThe efficacy and mechanism of Fufang Danshen dripping pills (FFDS) in the secondary prevention of stable coronary heart disease (SCHD) is currently undetermined. This study aims to investigate the efficacy and preliminary mechanism by which FFDS may impact the progression of SCHD.MethodsBased on randomization, we administered oral FFDS to 30 patients with SCHD in addition to conventional treatment for 30 days. After treatment, three-months major adverse cardiovascular events (MACE) were assessed as the primary outcome. Additionally, we evaluated the patients' Seattle Angina Questionnaire score, blood pressure, circulating levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, C-reactive protein, platelets, alanine aminotransferase, aspartate aminotransferase, serum creatinine, and fasting blood glucose as the secondary outcomes. Furthermore, we utilized mass spectrometry analysis, network pharmacology, and lipidomics to predict the potential mechanisms of FFDS in the treatment of SCHD.ResultsFollowing treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P = 0.013) and a reduction in the frequency of angina episodes (P = 0.021). We conducted mass spectrometry analysis on FFDS and identified 236 chemical components. Lipidomics further confirmed triglycerides as key lipids affected by FFDS. By integrating these findings with network pharmacology targets, we highlighted the potential roles of LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT in fat digestion, absorption, and metabolism pathways, suggesting their involvement in FFDS's treatment of SCHD by reducing triglycerides.ConclusionIn individuals with SCHD, the administration of FFDS has been shown to effectively reduce circulating triglyceride levels and decrease the frequency of angina episodes. This therapeutic effect is likely due to the active components of FFDS targeting key proteins: LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT.Clinical Trial Registrationhttps://www.chictr.org.cn/, identifier (ChiCTR2400080149).https://www.frontiersin.org/articles/10.3389/fcvm.2025.1506917/fullFufang Danshen dripping pillsstable coronary heart diseasetriglyceridesangina frequencylipidomics |
| spellingShingle | Li-qin Meng Li-qin Meng Pei-ying Huang Qing-min Li Yu-chao Feng Yu-chao Feng Yu-chao Feng Ding-jian Li Guang-long Wu Bo-wen Ao Guo-chao Wu Guo-xiong Zhang Bo-jun Chen Bo-jun Chen Bo-jun Chen Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial Frontiers in Cardiovascular Medicine Fufang Danshen dripping pills stable coronary heart disease triglycerides angina frequency lipidomics |
| title | Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial |
| title_full | Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial |
| title_fullStr | Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial |
| title_full_unstemmed | Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial |
| title_short | Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial |
| title_sort | therapeutic effect and potential mechanism of fufang danshen dripping pills for stable coronary heart disease a randomized controlled trial |
| topic | Fufang Danshen dripping pills stable coronary heart disease triglycerides angina frequency lipidomics |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1506917/full |
| work_keys_str_mv | AT liqinmeng therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT liqinmeng therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT peiyinghuang therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT qingminli therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT yuchaofeng therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT yuchaofeng therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT yuchaofeng therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT dingjianli therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT guanglongwu therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT bowenao therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT guochaowu therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT guoxiongzhang therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT bojunchen therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT bojunchen therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial AT bojunchen therapeuticeffectandpotentialmechanismoffufangdanshendrippingpillsforstablecoronaryheartdiseasearandomizedcontrolledtrial |